Table 1.
Baseline characteristics of the included studies
| Study/year | Region | Design | Population | Subject (%women) | Age/ Range of mean | Ascertainment of falls | Falls number (%) | Follow-up duration |
Punctuation NOS |
DM diagnosis (DM number) |
|---|---|---|---|---|---|---|---|---|---|---|
| Schwartz et al. (2002) [32] | USA | Prospective cohort study | Community | 9.249 (100% women) | 73.5 ± 5.0 | Postcard / phone | 1,640 (18%) | 2 years | 7 | Self-reports (629) |
| Maurer et al (2005) [30] | USA | Prospective cohort study | Long-stay institution | 139 (84% women) | 88 ± 7 | Berg balance scale | 49 | Range 97-8854 days | 8 | Prescription of oral hypoglycemic agent or insulin therapy (extracted from medical records) (18) |
| Volpato et al (2005) [29] | USA | Cohort | Community | 1.002 (100% women) | 75.3 ± 6.5 | Questionnaire | 26,5 | 3 years | 8 | Specific disease investigation algorithm developed for this study (136) |
| Tilling et al. (2006) [35] | UK | Cross-sectional prospective | Hospital | 77 (58.5% women) | 73 | Questionnaire | 39% | 5 months | 5 | Self-reports (77) |
| Schwartz et al. (2008) [28] | USA | Cohort | Community | 3.075 (44.6% women) | 73.6 ± 2.7 | Questionnaire /self-reports | 23% | 5 years | 8 | Self-report, use of hypoglycemic medication or an elevated fasting glucose level (≥126 mg/dl) or 2-hour oral glucose tolerance test (≥200 mg/dl) (719) |
| Pijpers et al. (2011) [20] | NL | Cohort | Community | 1.145 (49.8% women) | 75.4 ± 6.5 | Calendar | 232 (20,3%) | 3 years | 8 | Self-report and use of glucose-lowering medication (85) |
| Roman de Mettilinge et al (2013) [31] | BE | Prospective cohort | Community | 199 (68.3% women) | 76.9 ± 9.4 | Questionnaire | 56 (28,4%) | 12 months | 6 | General practitioner or specialist physician confirmed the presence or absence of DM (104) |
| Yau et al (2013) [33] | USA | Prospective cohort | Community | 3.075 (52% women) | 73.7 ± 2.8 | Medical record | 293 | 10 years | 7 | Self-reported medical diagnosis, self-reported use of antidiabetic medications, elevated fasting glucose level (≥ 126 mg/dL) or elevated levels on a 2-hour oral glucose tolerance test (≥ 200 mg/dL) (719) |
| Bruce et al. (2015) [19] | AU | Cross-sectional | Community | 186 (50% women) | 70.3 ± 10.1 | Questionnaire | 39 (20,9%) | -* | 4 | Self-report and fasting glucose levels (186) |
| Chiba et al. (2015) [36] | JP | Cross-sectional retrospective | Community | 211 (70,88% women) | 76.2 ± 6.8 | Questionnaire | 62 | Every 3 months for 3 years | 5 | Self-reports (168) |
| Randolph et al (2019) [27] | USA | Cohort | Community | 22.200 (63.3% women) | 78.3 ± 6.9 | Medical record | 411 | 5 years | 6 | Medical record (11.000) |
| Rashedi et al (2019) [34] | IR | Cross-sectional | Community | 220 (58% women) | 69.82 ±9.9 | Questionnaire | 77 (38,5%) | -* | 3 | Medical record (220) |
Source: Research data, 2022. -*, Did not provide data on the duration of follow-up
DM Diabetes Mellitus, NOS New Castle Ottawa